Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma: Russian Retail Market of Cosmetic Injectables Shows Double-Digit Increase for the Second Year in a Row

Wednesday, September 11, 2024

In the first half of 2024, the Russian retail market of beauty fillers and biorevitalization products was 10.9 billion rubles (retail prices, VAT included), up 21% from January–June 2023. In physical terms, it was 2.2 million minimum dosage units (MDU), up 12% from the same period last year. At the same time, the total sales in 2023 were 18.5 billion rubles, or 3.9 million MDUs, up 20% in monetary and up 27% in physical terms.

The main distribution channel for cosmetic injectables are beauty clinics, where the product can both be purchased and administered. In January–June 2024, the clinics accounted for around 94.8% of the sales in monetary terms against 93.4% in 2022. Another important distribution channel is pharmacies, with 4.4%. However, the role of pharmacies keeps falling; back in 2022, they accounted for 6.5%. Finally, less than 1% of cosmetic injectables are distributed online. In physical terms, marketplaces accounted for 7.4% of the sales, mostly through Wildberries, where the Korean biorevitalization product Hyaron is distributed.

Fillers accounted for 62.6% of the sales in monetary terms, and biorevitalization and polylactic acid products accounted for the remaining 37.4%. In physical terms, it was slightly different; due to their high cost, fillers accounted for only 37% of the sales. The average price for a filler in the analyzed period was over 8,000 rubles, three times that of a biorevitalization product, 2,600 rubles. The most expensive products are polylactic acid injections, with over 25,000 rubles.

The sales differed greatly from region to region. For example, Moscow accounted for 35.8% of the sales of fillers and biorevitalization products, which is 3.8 billion rubles, or nearly 745,000 MDUs (33.6%). St. Petersburg ranked second with 9.4% (over 1 billion rubles in sales). Other regions were far behind; even Krasnodar Krai, which ranked third, accounted for only 4.2% of the sales (452.5 million rubles). In Moscow Oblast, the sales were 412.7 million rubles (3.8%). However, the sales in this region grew the fastest among the other top-10 regions; they went up 67% in monetary terms, while the sales in physical terms grew five times against January–June 2023.

Sales dynamics of filers and biorevitalizers on the retail market in Russia

*including manufacturing output of foreign companies at owned and contract plants